Dr. Tyrone C. Malloy: Urology-Urinary Incontinence
Continued A Phase 3, Randomized, Double Blind, Parallel Group Active Controlled, Multi-Center Long-Term Study to Assess the Efficacy and Safety of the Beta-3 Agonist X in Subjects with Symptoms of Overactive Bladder
Principal Investigator
Sponsor: Astellas Phrama US
A Phase 3, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Assess the Efficacy and Safety of the Beta-3 Agonist X in Subjects with Symptoms of Overactive Bladder
Principal Investigator
Sponsor: Astellas Phrama US
Study of XXX In Women Of Different Demographic Characteristics And Co-Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety.
Principal Investigator
Sponsor: Eli Lilly
Symptom Specific Effectiveness of XX in Patients with
Symptoms of Overactive Bladder (OAB) in a Primary Care Setting. A Phase 4, Open Label, Single Arm, Non-Randomized Trial in Adult Patients with OAB
Principal Investigator
Sponsor: Pfizer
A randomized double-blind placebo and active Controlled efficacy and safety study of XX in patients with overactive bladder or urge urinary incontinence
Principal Investigator
Sponsor: Sanofi-Aventis
A Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing with XXXXX Topical Gel to Treat the Symptoms of Overactive Bladder
Principal Investigator
Sponsor: Watson Pharmaceutical
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg XXXX Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated with Uncomplicated Urinary Tract Infection.
Principal Investigator
Sponsor: Pennacle
Dr. Tyrone Malloy: Urinary Incontinence
